Your TSH Is Normal, Yet You Feel Hypothyroid. Here's Why.

DIO2 encodes deiodinase type 2, the enzyme responsible for converting inactive T4 thyroid hormone into active T3 in your tissues. This conversion doesn’t happen in your bloodstream; it happens at the cellular level, inside the mitochondria of cells that need energy. Your brain, heart, and metabolic tissues depend on this local T3 production to function. Without efficient DIO2 activity, you have abundant T4 but starving cells.

The DIO2 Thr92Ala variant, found in roughly 12-15% of people, significantly impairs this conversion enzyme. Carriers of the Ala/Ala genotype convert T4 to T3 at a fraction of the normal rate, leaving tissues functionally hypothyroid even when circulating T4 looks adequate. Your pituitary sees enough T4, so TSH stays normal. Your peripheral tissues don’t see enough T3, so you feel exhausted.

This is the gene variant that explains why some people feel dramatically better on T3 supplementation or a combination of T4 and T3, while others do fine on T4 alone. If you carry the Ala/Ala variant, your body is essentially asking for help: it cannot efficiently do the conversion job itself. Your fatigue, brain fog, weight gain, and cold intolerance are your tissues signaling that they need active T3, not just the raw material to make it.

TPO, thyroid peroxidase, is the enzyme that catalyzes the very first step of thyroid hormone production: binding iodine to tyrosine molecules to create T3 and T4. Your thyroid cannot manufacture any hormone without TPO working correctly. It’s the gatekeeper. TPO also requires selenium as a cofactor, meaning the enzyme only functions when selenium is present and your gene variant allows efficient enzyme assembly.

Variants in the TPO gene, found in roughly 20-30% of the population, reduce enzyme efficiency and increase susceptibility to Hashimoto’s thyroiditis and hypothyroidism. People with TPO variants often have lower TPO enzyme activity, meaning less T4 and T3 production even when iodine and selenium are abundant. Your pituitary detects the shortfall and raises TSH to compensate. But if the variant is severe enough, even high TSH can’t force your thyroid to produce enough hormone. You’re stuck.

You may also develop thyroid antibodies because a less efficient TPO enzyme is more likely to be recognized as foreign by your immune system. This creates a second problem: immune-driven inflammation that further damages thyroid tissue. Your fatigue, cold sensitivity, and slow metabolism aren’t just from low hormone; they’re from running a thyroid that’s working twice as hard to produce half as much.

TSHR encodes the TSH receptor, the protein on your thyroid cell surface that listens to the pituitary gland’s signal to produce hormone. Think of it as the radio antenna your thyroid uses to receive instructions. If the antenna is tuned differently, the signal gets through but may be interpreted wrongly. Some people’s TSH receptors are highly sensitive and respond to minimal TSH. Others require more TSH stimulation before producing hormone. That’s genetics.

Variants in TSHR, present in roughly 10-20% of the population, alter TSH receptor sensitivity and shift the range at which your thyroid begins responding to pituitary signals. People with certain TSHR variants may require higher TSH to trigger adequate hormone production, or they may produce hormone inefficiently at normal TSH levels. The result is the same: normal TSH on your blood test but inadequate T4 and T3 circulating in your tissues. Your pituitary is communicating normally; your thyroid is just not listening efficiently.

This is especially relevant if you’ve been told your TSH is at the high end of normal (3-4 mIU/L) but your doctor isn’t concerned. If you carry a TSHR variant that reduces receptor sensitivity, that TSH might be your pituitary’s way of frantically signaling a thyroid that won’t cooperate. You feel cold, sluggish, and fat because your body is downregulating metabolism to match the low hormone your thyroid can produce.

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that activates folate into the methyl donor that powers methylation reactions throughout your body. Thyroid hormone metabolism is methylation-dependent. T3 must be methylated to cross cell membranes and bind to thyroid receptors inside cells. Thyroid antibody production is also controlled by methylation capacity. If your MTHFR gene carries the C677T variant, your methylation cycle runs slower, and thyroid hormone activation stalls.

The MTHFR C677T variant, present in roughly 40% of people of European ancestry, reduces methylation enzyme efficiency by 30-40%. Carriers often have impaired thyroid hormone metabolism and dysregulated thyroid antibodies, meaning they feel hypothyroid symptoms and may develop autoimmune thyroid disease. You can take thyroid replacement, but if your methylation pathway is bottlenecked, that hormone cannot be properly metabolized and delivered to where it’s needed. You remain symptomatic.

MTHFR variants also impair selenium-dependent enzyme function, which compounds thyroid problems because selenium is required for both TPO and DIO2 to work. Your thyroid is starved of raw material, your conversion enzyme is weak, and your methylation engine is struggling. The result is a cascade of thyroid dysfunction that standard replacement therapy alone cannot fix.

VDR encodes the vitamin D receptor, the protein that allows your cells to respond to vitamin D. Vitamin D is not just a nutrient; it’s a hormone that regulates immune tolerance. When VDR signaling is deficient, your immune system cannot maintain its tolerance for your own thyroid tissue. Autoimmune thyroiditis (Hashimoto’s) becomes more likely. Even if your thyroiditis hasn’t progressed to antibody production yet, VDR variants predict who will develop autoimmune thyroid disease and who will remain functionally euthyroid.

Common VDR variants (BsmI, ApaI, TaqI polymorphisms) alter vitamin D receptor sensitivity and are found in roughly 40-50% of the population, depending on ancestry. People with VDR variants that reduce receptor function often require higher vitamin D levels to maintain immune tolerance and prevent thyroid antibody activation. If your vitamin D is low-normal (30-40 ng/mL) and you carry a VDR variant, your immune system is running without brakes. Thyroid autoimmunity can quietly progress.

You may not feel obviously sick, but your thyroid is under siege. TSH may creep up slightly. T3 and T4 may drift lower. Eventually you cross the threshold into overt hypothyroidism. By that point, immune damage is done. The solution is to identify the VDR variant and optimize vitamin D aggressively early.

COMT, catechol-O-methyltransferase, clears epinephrine and norepinephrine from your bloodstream. These are your stress hormones. They’re supposed to surge during threat, then clear quickly so your body can recover. But if you carry a COMT variant that slows catecholamine clearance, stress hormones hang around in your blood long after the stressor is gone. Your nervous system stays activated. Your HPA axis stays engaged. Your adrenal glands stay stimulated.

The COMT Val158Met variant, found in roughly 25% of people homozygous for the slow allele, impairs epinephrine and norepinephrine clearance by up to 40%. Slow COMT carriers experience chronic adrenal activation, burnout susceptibility, and paradoxical fatigue despite feeling wired. This chronic stress state suppresses TSH production and downregulates thyroid receptor expression. Your thyroid is drowning in a sea of stress hormones. You feel simultaneously anxious and exhausted, wired yet unable to sleep.

Your TSH may actually be lower than it should be because your pituitary is signaling your thyroid to shut down during perceived chronic threat. Your T4 and T3 are low not because your thyroid can’t produce but because your adrenal system is sabotaging thyroid function to conserve energy for “survival.” You cannot fix this with thyroid medication alone. You must reduce adrenal load.